Citations

Clear

439 citation(s) found for "Stone, M".

An Inherited Genetic Variant in CEP72 Promoter Predisposes to Vincristine‐Induced Peripheral Neuropathy in Adults With Acute Lymphoblastic Leukemia
Diouf, B , Crews, Kristine R. , Pei, D, Laumann, Kristina, Mandrekar, S. J., Luger, Selina M. , Stone, RM, We, Evans, Loh, Mignon L. , Stock, Wendy , Cheng, Christopher H.K. , Advani, Anjali S. , Larson, Richard A. , Crews, Kristine R , Loh, Mignon L

Mayo Clinic

Clinical Pharmacology & Therapeutics | September 12, 2016 | Volume: 101 | Issue: 3 | Pages: 391-395

10.1002/cpt.506 | PMID 27618250 Get It

Peripheral neuropathy is a major toxicity of vincristine, yet no strategies exist for identifying adult patients at high‐risk. We used a case–control design of 48 adults receiving protocol therapy for acute lymphoblastic leukemia (ALL) who developed vincristine‐induced neuropathy (NCI grade 2–4) during treatment, and 48 matched controls who did not develop grade 2–4 neuropathy. Peripheral neuropathy was prospectively graded by National Cancer Institute (NCI) criteria. CEP72 promoter genotype (rs924607) was determined using polymerase chain reaction (PCR)‐based single nucleotide polymorphism (SNP) genotyping. Frequency of the CEP72 T/T genotype was higher in cases (31% vs. 10%, P = 0.0221) and the incidence of vincristine‐induced neuropathy (grades 2–4) was significantly higher in patients homozygous for the CEP72 T/T genotype. 75% of the 20 patients homozygous for the CEP72 T allele developed grade 2–4 neuropathy, compared to 44% of patients with CEP72 CC or CT genotype (P = 0.0221). The CEP72 polymorphism can identify adults at increased risk of vincristine‐induced peripheral neuropathy.
The Pharmacogenomic Association of Fcγ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Cartin‐Ceba, Rodrigo , Indrakanti, Divya, Stone, John H., Hoffman, Gary S., Kallenberg, Cees G. M., Langford, Carol A. , Clair, E. William St. , Seo, Philip , Tchao, Nadia K., Ytterberg, Steven R. , Brunetta, Paul , Song, Huijuan , Birmingham, Dan, Specks, Ulrich , Merkel, Peter A. , Spiera, Robert , Monach, Paul A. , Rovin, Brad H.

Mayo Clinic

Arthritis & Rheumatology | August 3, 2016 | Volume: 69 | Issue: 1 | Pages: 169-175

10.1002/art.39822 | PMID 27482943 Get It

ObjectiveThe Rituximab in ANCA‐Associated Vasculitis (RAVE) trial compared rituximab to cyclophosphamide as induction therapy for the treatment of antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis. We undertook the current study to determine whether known single‐nucleotide polymorphisms (SNPs) for Fcγ receptors (FcγR) or cytochrome P450 (CYP) enzymes were associated with the response to treatment with rituximab and cyclophosphamide, respectively.MethodsFunctional SNPs for FcγR (FcγRIIa 519G>A, FcγRIIb 695T>C, FcγRIIIa 559T>G) and CYP enzymes (CYP2B6 1459C>T, CYP2C19 681G>A) were analyzed by direct sequencing of polymerase chain reaction–amplified genomic DNA. Each SNP was tested as a predictor of complete remission at 6 months or remission with continued prednisone administration using logistic regression and including the covariates of baseline Birmingham Vasculitis Activity Score for Wegener's Granulomatosis, ANCA type, and new versus relapsing disease. The associations of these SNPs with the secondary outcomes of time to complete remission, time to relapse, or time to B cell reconstitution were analyzed by Cox proportional hazard tests.ResultsNo significant associations were identified between complete remission and any FcγR genotype in the rituximab group or any CYP genotype in the cyclophosphamide group. However, when the treatment groups were combined, an association was found between the 519AA genotype of FcγRIIa and complete remission (P = 0.01). The 519AA genotype predicted complete remission (P = 0.006) and a shorter time to complete remission (P < 0.001).ConclusionThe finding that the homozygous FcγRIIa 519AA variant was associated with complete response and a shorter time to complete response in the RAVE trial, independent of treatment type, implies that FcγRIIa may be broadly involved in disease pathogenesis and response to therapy.
Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia
Bhatnagar, Bhavana , Eisfeld, Ann‐Kathrin , Mrózek, Krzysztof , Lucas, David , Kohlschmidt, Jessica, Blum, William , Kolitz, Jonathan E. , Stone, Richard M. , Bloomfield, Clara D. , Byrd, John C. , Byrd, John C. , Nicolet, Deedra , Blachly, James S. , Orwick, Shelley J. , Byrd, John C

Mayo Clinic

British Journal of Haematology | August 2, 2016 | Volume: 175 | Issue: 2 | Pages: 226-236

10.1111/bjh.14254 | PMID 27476855 Get It

SummarySomatic mutation of the DNMT3A gene at the arginine R882 site is common in acute myeloid leukaemia (AML). The prognostic significance of DNMT3A R882 mutation clearance, using traditional diagnostic next generation sequencing (NGS) methods, during complete remission (CR) in AML patients is controversial. We examined the impact of clearing DNMT3A R882 mutations at diagnosis to the detectable threshold of ˂3% during CR on outcome in 56 adult AML patients. Mutational remission, defined as clearance of pre‐treatment DNMT3A R882 and all other AML‐associated mutations to a variant allele frequency ˂3%, occurred in 14 patients whereas persistent DNMT3A R882 mutations were observed in 42 patients. There were no significant differences in disease‐free or overall survival between patients with and without DNMT3A R882 mutation clearance. Patients with persistent DNMT3A R882 who cleared all other AML mutations and did not acquire new mutations (n = 30), trended towards longer disease‐free survival (1·6 vs. 0·6 years, P = 0·06) than patients with persistence of DNMT3A R882, in addition to other mutations or acquisition of new AML‐associated mutations, such as those in TET2, JAK2, ASXL1 and TP53 (n = 12). These data demonstrate that DNMT3A R882 mutations, as assessed by traditional NGS methods, persist in the majority of AML patients in CR.
Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3–Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Pepper, Ruth J., Draibe, Juliana , Caplin, Ben , Hoffman, Gary S., Kallenberg, Cees G. M., Langford, Carol A. , Seo, Philip , Clair, E. William St. , Tchao, Nadia K., Stone, John H., Fervenza, Fernando C. , Monach, Paul A. , Spiera, Robert , Specks, Ulrich , Merkel, Peter A. , Salama, Alan David

Mayo Clinic

Arthritis & Rheumatology | July 18, 2016 | Volume: 69 | Issue: 1 | Pages: 185-193

10.1002/art.39814 | PMID 27428710 Get It

Objective S100A8/A9 (calprotectin) has shown promise as a biomarker for predicting relapse in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). This study was undertaken to investigate serum S100A8/A9 level as a biomarker for predicting future relapse in a large cohort of patients with severe AAV. Methods Serum levels of S100A8/A9 were measured at baseline and months 1, 2, and 6 following treatment initiation in 144 patients in the Rituximab in ANCA‐Associated Vasculitis trial (cyclophosphamide/azathioprine versus rituximab [RTX] for induction of remission) in whom complete remission was attained. Results Patients were divided into 4 groups: proteinase 3 (PR3)–ANCA with relapse (n = 37), PR3‐ANCA without relapse (n = 56), myeloperoxidase (MPO)–ANCA with relapse (n = 6), and MPO‐ANCA without relapse (n = 45). Serum S100A8/A9 level decreased in all groups during the first 6 months of treatment. The percentage reduction from baseline to month 2 was significantly different between patients who experienced a relapse and those who did not in the PR3‐ANCA group ( P = 0.046). A significantly higher risk of relapse was associated with an increase in S100A8/A9 level between baseline and month 2 ( P = 0.0043) and baseline and month 6 ( P = 0.0029). Subgroup analysis demonstrated that patients treated with RTX who had increased levels of S100A8/A9 were at greatest risk of future relapse ( P = 0.028). Conclusion An increase in serum S100A8/A9 level by month 2 or 6 compared to baseline identifies a subgroup of PR3‐ANCA patients treated with RTX who are at higher risk of relapse by 18 months. Since RTX is increasingly used for remission induction in PR3‐ANCA–positive patients experiencing a relapse, S100A8/A9 level may assist in identifying those patients requiring more intensive or prolonged treatment.
Myeloperoxidase–Antineutrophil Cytoplasmic Antibody (ANCA)–Positive and ANCA‐Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets
Miloslavsky, Eli M. , Lu, Na , Unizony, Sebastian , Seo, Philip , Langford, Carol A. , Hoffman, Gary S., Kallenberg, Cees G. M., Clair, E. William St. , Tchao, Nadia K., Stone, John H., Fervenza, Fernando, Choi, Hyon K. , Merkel, Peter A. , Spiera, Robert , Fervenza, Fernando C. , Monach, Paul A. , Specks, Ulrich

Mayo Clinic

Arthritis & Rheumatology | July 18, 2016 | Volume: 68 | Issue: 12 | Pages: 2945-2952

10.1002/art.39812 | PMID 27428559 Get It

ObjectiveTo examine the relationship of antineutrophil cytoplasmic antibody (ANCA) type and ANCA‐associated vasculitis (AAV) diagnosis with demographic features, disease manifestations, and clinical outcomes. We focused on patients who account for the differences between ANCA type and disease type classifications: anti‐myeloperoxidase (MPO)–ANCA–positive and ANCA‐negative patients with granulomatosis with polyangiitis (Wegener's) (GPA).MethodsWe performed a pooled analysis of the Wegener's Granulomatosis Etanercept Trial and the Rituximab in ANCA‐Associated Vasculitis trial comparing patients with MPO‐ANCA–positive GPA and patients with ANCA‐negative GPA to patients with proteinase 3 (PR3)–ANCA–positive GPA and patients with MPO‐ANCA–positive microscopic polyangiitis (MPA).ResultsOf the 365 patients analyzed, 273 (75%) had PR3‐ANCA–positive GPA, 33 (9%) had MPO‐ANCA–positive GPA, 15 (4%) had ANCA‐negative GPA, and 44 (12%) had MPO‐ANCA–positive MPA. MPO‐ANCA–positive GPA patients were younger at diagnosis compared to MPO‐ANCA–positive MPA patients (53 versus 61 years; P = 0.02). Their disease manifestations and rates of relapse were similar to those of PR3‐ANCA–positive GPA patients. Relapse was more frequent in MPO‐ANCA–positive GPA patients than in patients with MPO‐ANCA–positive MPA at trial entry as well as at 12 and 18 months. ANCA‐negative patients with GPA had lower Birmingham Vasculitis Activity Score for Wegener's Granulomatosis scores at trial entry than PR3‐ANCA–positive patients with GPA (4.5 versus 7.7; P < 0.01), primarily because of a lower prevalence of renal involvement.ConclusionWe were unable to demonstrate important clinical differences between MPO‐ANCA–positive and PR3‐ANCA–positive patients with GPA. The risk of relapse was associated more closely with disease type than with ANCA type in this patient cohort. These findings deserve consideration in the assessment of relapse risk in patients with AAV.
Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia
Castillo, Jorge J. , García‐Sánz, Ramón , Hatjiharissi, Evdoxia , Kyle, Robert A. , Leleu, Xavier , McMaster, Mary L. , Merlini, Giampaolo , Morra, Enrica, Owen, Roger G., Poulain, Stéphanie , Stone, Marvin J., Tam, Constantine S. , Varettoni, Marzia , Dimopoulos, Meletios Α. , Kastritis, Efstathios , Minnema, Monique C , Treon, Steven P. , Merlini, Giampaolo , Dimopoulos, Meletios A , Tam, Constantine S , Kastritis, Efstathios , Garcia-Sanz, Ramon , Castillo, Jorge J , Varettoni, Marzia

Mayo Clinic

British Journal of Haematology | July 5, 2016 | Volume: 175 | Issue: 1 | Pages: 77-86

10.1111/bjh.14196 | PMID 27378193 Get It

SummaryThe diagnosis of Waldenström macroglobulinaemia (WM) can be challenging given the variety of signs and symptoms patients can present. Furthermore, once the diagnosis of WM is established, the initial evaluation should be thorough as well as appropriately directed. During the 8th International Workshop for WM in London, United Kingdom, a multi‐institutional task force was formed to develop consensus recommendations for the diagnosis and initial evaluation of patients with WM. In this document, we present the results of the deliberations that took place to address these issues. We provide recommendations for history‐taking and physical examination, laboratory studies, bone marrow aspiration and biopsy analysis and imaging studies. We also provide guidance on the initial evaluation of special situations, such as anaemia, hyperviscosity, neuropathy, Bing‐Neel syndrome and amyloidosis. We hope these recommendations serve as a practical guidance to clinicians taking care of patients with a suspected or an established diagnosis of WM.
Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis
Mills, John R. , Dasari, Surendra , Ladwig, Paula M. , Hummel, Amber M., Cheu, Melissa , Murray, David , Snyder, Melissa R., Hoffman, Gary S., Kallenberg, Cees G. M., Langford, Carol A. , Seo, Philip , Clair, E. William St. , Stone, John H., Barnidge, David R. , Snyder, M , Cornec, Divi, Murray, David L., Willrich, Maria A, Cornec, Divi , Willrich, Maria Alice V. , Snyder, Melissa R., Merkel, Peter A. , Monach, Paul A. , Spiera, Robert , Specks, Ulrich , Snyder, Michael

Mayo Clinic

Analytical Chemistry | May 26, 2016 | Volume: 88 | Issue: 12 | Pages: 6317-6325

10.1021/acs.analchem.6b00544 | PMID 27228216 Get It

Abstract Therapeutic monoclonal immunoglobulins (mAbs) are used to treat patients with a wide range of disorders including autoimmune diseases. As pharmaceutical companies bring more fully humanized therapeutic mAb drugs to the healthcare market analytical platforms that perform therapeutic drug monitoring (TDM) without relying on mAb specific reagents will be needed. In this study we demonstrate that liquid-chromatography?mass spectrometry (LC?MS) can be used to perform TDM of mAbs in the same manner as smaller nonbiologic drugs. The assay uses commercially available reagents combined with heavy and light chain disulfide bond reduction followed by light chain analysis by microflow-LC?electrospray ionization-quadrupole-time-of-flight mass spectrometry (ESI-Q-TOF MS). Quantification is performed using the peak areas from multiply charged mAb light chain ions using an in-house developed software package developed for TDM of mAbs. The data presented here demonstrate the ability of an LC?MS assay to quantify a therapeutic mAb in a large cohort of patients in a clinical trial. The ability to quantify any mAb in serum via the reduced light chain without the need for reagents specific for each mAb demonstrates the unique capabilities of LC?MS. This fact, coupled with the ability to phenotype a patient?s polyclonal repertoire in the same analysis further shows the potential of this approach to mAb analysis.
Dual-Energy CT for Quantification of Urinary Stone Composition in Mixed Stones: A Phantom Study
Huang, Alice E. , Montoya, Juan , Duan, Xinhui , Williams, James C. , Huang, Alice, Cardona, Juan Montoya, Leng, Shuai , McCollough, Cynthia H.

Mayo Clinic

American Journal of Roentgenology | May 25, 2016 | Volume: 207 | Issue: 2 | Pages: 321-329

10.2214/ajr.15.15692 | PMID 27224260 Get It

USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds
Walker, Matthew P. , Quick, Laura , Orgel, Kelly, Ryan, Meagan B. , Gupta, Priti , Henrich, Ian C. , Marine, Shane, Roberts, Brian S. , Arthur, William T., Berndt, Jason D. , Oliveira, André M. , Virshup, David M. , Chou, Margaret M. , Major, Michael B. , Virshup, David M , Madan, Babita , Walker, Matthew P., Young, Robert , Ferrer, Marc , Moon, Randall T.

Mayo Clinic

Proceedings of the National Academy of Sciences | May 10, 2016 | Volume: 113 | Issue: 21 | Pages: No page available

10.1073/pnas.1605691113 | PMID 27162353 Get It

Significance Ubiquitin-specific protease 6 (USP6) is a deubiquitylase that is overexpressed by chromosome translocation in two human neoplasms, aneurysmal bone cyst and nodular fasciitis. The relevant substrates of this ubiquitin-specific protease are not clear. Here, we identify the Wnt receptor Frizzled (Fzd) as a key target of the USP6 oncogene. Increased expression of USP6 increases the membrane abundance of Fzd, and hence increases cellular sensitivity to Wnts. USP6 opposes the activity of the ubiquitin ligase and tumor suppressor ring finger protein 43 (RNF43). This study identifies a new mechanism for pathological Wnt pathway activation in human disease and suggests a new approach to regulate Wnt activity therapeutically.
Re: Assessment of Stone Complexity for PCNL: A Systematic Review of the Literature, How Best Can We Record Stone Complexity in PCNL? (From: Withington J, Armitage J, Finch W, et al. J Endourol 2016;30:13–23)
Ingimarsson, Johann P. , Hyams, Elias S. , Pais, Vernon M., Ingimarsson, Johann Pall, Dagrosa, Lawrence M.

Mayo Clinic

Journal of Endourology | February 18, 2016 | Volume: 35 | Issue: 5 | Pages: 753-753

10.1089/end.2015.0852 | PMID 26890191 Get It